Can the systemic inflammation score be used to predict prognosis in gastric cancer patients undergoing surgery? A systematic review and meta-analysis

Shuai Liu¹, Xiaowei Yu², Feifei Ye¹ and Liangxian Jiang¹*

¹Department of Gastrointestinal Surgery, Taizhou Hospital of Zhejiang Province, Taizhou, China, ²Department of Day Care Ward, Taizhou Hospital of Zhejiang Province, Taizhou, China

Background: Inflammatory markers are being increasingly used to predict the prognosis of cancer patients. We hereby conducted the first meta-analysis assessing the association between systemic inflammation score (SIS) and prognosis of gastric cancer patients undergoing surgical intervention.

Methods: A literature search was carried out on PubMed, CENTRAL, Scopus, and Embase up to 3rd June 2022 for relevant studies. Adjusted data reported as hazard ratios (HR) was combined in a random-effects model.

Results: A total of seven studies with 5,338 patients could be included. All studies were from either China or Japan and published in the last four years. Meta-analysis showed that higher SIS scores (1 or 2) were significant predictors of poor overall survival (OS) in gastric cancer patients (HR: 1.25 95% CI: 1.05, 1.49, I² = 11%). Similarly, the meta-analysis demonstrated that an SIS score of 2 was associated with poor OS as compared to scores of 0/1 (HR: 2.53 95% CI: 1.30, 4.89, I² = 45%). Data on disease-free survival (DFS) was scarce to draw conclusions.

Conclusion: The SIS score can be a simple and useful tool to predict OS in gastric cancer patients undergoing surgery. Data on DFS is scarce and conflicting. Future studies should report using standard reference groups and provide data on DFS to enhance current evidence.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/#searchadvanced, identifier: CRD42022335548.

Keywords
gastric cancer, inflammation, prognosis, survival, surgery

Introduction

Gastric cancer is a serious health problem worldwide owing to its high prevalence and dismal survival rates (1). While data indicates that the total burden of gastric cancer may be on a decline due to a reduced number of smokers and a decrease in Helicobacter pylori prevalence, the burden of the disease is large enough to concern amongst healthcare professionals (2). Indeed, gastric cancer is the fourth commonest
malignancy and the third leading cause of cancer-related death in the world (3). Many patients with gastric cancer are diagnosed in advanced stage and metastasis or recurrence are important contributors to poor prognosis in such patients. At present, the American Joint Committee on Cancer (AJCC) proposed tumor-node-metastasis (TNM) classification is one of the commonest prognostic models used worldwide (4). However, precise prediction is still difficult and there is a need for simple and easily measurable prognostic factors for routine clinical practice.

Cancer inflammation has been explored recently to estimate patient prognosis. Studies have shown that cancer-related inflammation can cause DNA damage, mutations, proliferation of blood vessels, as well as growth, invasion, and metastasis of cancer cells (5, 6). Furthermore, the microenvironment surrounding the tumor is not only influenced by cancer itself but also depends on the host inflammatory response (7). In this context, several blood-based inflammatory markers like the neutrophil, lymphocyte, monocyte, and platelet count; albumin level; alcohol dehydrogenase; C-reactive protein (CRP), and combinations like neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) have been used to predict outcomes in patients with cancer (8–10).

One such marker which is recently being used is the systemic inflammation score (SIS), which is based on the combination of serum albumin and LMR scores in the perioperative period. The SIS has been demonstrated to be of good prognostic ability in patients with lung, colorectal and esophageal cancer (11–13). The strength of the score lies in the combined use of albumin which is a nutritional marker and LMR which is an inflammatory marker (13). The SIS score ranges from 0 to 2. Generally, patients with albumin levels of ≥4.0 g/dL and LMR ≥ 4.44 are classified with a score of 0, those with either albumin <4.0 g/dL or LMR < 4.44 are given a score of 1, and those with albumin <4.0 g/dL and LMR < 4.44 were given a score of 2 (11, 12). Studies have shown that the score is higher in cancer patients with either albumin <4.0 g/dL or LMR < 4.44. In recent times, several studies have also reported the prognostic ability of SIS for gastric cancer patients but with varying results. At this point, it is unclear if SIS can be clinically used to predict outcomes of gastric cancer. Hence, we conducted the first systematic review and meta-analysis to assess if SIS is associated with outcomes in gastric cancer patients undergoing surgical intervention.

Material and methods

Inclusion and exclusion criteria

Our review was prospectively registered on PROSPERO (No. CRD42022335548) and reported based on the recommendations of the PRISMA statement (14). We included all types of studies reporting the association between perioperative SIS and outcomes of gastric cancer patients undergoing surgical intervention. The outcomes were to be either overall survival (OS) or disease-free survival (DFS) reported as adjusted ratios. We excluded studies not reporting separate outcomes for gastric cancer or not including those with surgical intervention. Furthermore, case reports, reviews, and editorials were also not included. If there were two or more studies with overlapping datasets, the largest study was included in the review.

We looked across the databases of PubMed, CENTRAL, Scopus, and Embase up to 3rd June 2022 for eligible English-language studies. We used a combination of free-text and MeSH search terms namely, “gastric cancer”, “gastric carcinoma”, “gastric malignancy”, “systemic inflammation score”, “survival”; and “cancer” for the literature search. The search strings used for all databases are presented in Supplementary Table S1. The first set of search outcomes was checked by the article titles and abstracts to weed out non-relevant articles. Two reviewers then selected studies for full-text analysis and cross-checked them against the eligibility criteria mentioned earlier. Only studies fulfilling all criteria were included in the review. All disagreements between the reviewers were solved in consultation with another reviewer. The references of included studies were also cross-checked for any missed articles.

Details of the first author, year of publication, location of the study, study population, tumor stage, timing of measurement of SIS, tumor stage, sample size, age, male gender, histology, tumor location, surgery type, adjuvant chemotherapy, follow-up and adjusted ratios of the outcomes were extracted by two reviewers using a previously prepared word document. The outcomes of the review were OS and DFS.

Quality assessment of the studies was also carried out by two authors of the review using the Newcastle Ottawa Scale (NOS) for observational studies (15). The scale has three components: study population, comparability, and outcomes with each component awarded points based on the relevant questions. The highest score achievable is nine.

Statistical analysis

All of the included studies reported OS and DFS as hazard ratios (HR) with 95% confidence intervals (CI). These were combined to estimate the pooled effect size as HR in a random-effects model. We assessed inter-study heterogeneity using the $I^2$ statistic. $I^2$ = 25%–50% meant low, 50%–75% meant medium, and more than 75% meant substantial heterogeneity. As the total number of studies was few, we could not use funnel plots to look for publication bias. However, a sensitivity analysis was performed and individual studies were excluded from the meta-analysis to look out for any change in the significance of the results. We also assessed...
the relationship of high SIS (scores 1–2) and various clinicopathological features of gastric cancer by calculating odds ratios and 95% CI. The factors analyzed were age (≥70 years vs. <70 years), gender (male vs. female), tumor size (≥5 cm vs. <5 cm), location (lower third vs. other sites), differentiation (poorly differentiated vs. well differentiated), lymph node metastasis (present vs. absent), tumor stage (stage III vs. stage I–II). All analyses were done on "Review Manager" [RevMan, version 5.3; Nordic Cochrane Centre (Cochrane Collaboration), Copenhagen, Denmark; 2014]. Quantitative analysis was only performed if at least 3 studies were reporting numerical data otherwise, a qualitative assessment was carried out.

Results

The outcomes of the literature search at every stage are presented in detail in Figure 1. Out of 810 unique articles screened, 18 were assessed by their full texts. We excluded 11 studies not fulfilling the inclusion criteria and managed to include seven studies in this review (16–22).

The baseline details extracted from the studies are presented in Table 1. All seven studies were either from China or Japan and published in the past four years. Most studies including patients with stage I–III cancer. The definition of SIS was the same across all studies except one. Inagaki et al. (20) used the LMR value of 3.4 instead of 4.44 which was common in the remaining studies [Value of 3.4 indicates the modified SIS (mSIS)]. Albumin values were the same across the included studies. SIS was calculated based on presurgical blood investigation in all studies except for Hara et al. (19) which used 1-month post-surgical values. The total number of patients analyzed was 5,338. The median age was >55 in all studies. Male patients predominated compared to female patients across the included studies. Five studies included patients only with adenocarcinoma. The percentage of poorly differentiated tumors ranged from 22.2% to 70.7%. Patients undergoing total gastrectomy varied from 27.2% to 51.1%. Adjuvant chemotherapy was used in 24% to 77.5% of patients. Median follow-up ranged from 35 to 101 months. All were good quality studies with the NOS score of 7–8.

SIS and clinicopathological features

Details of clinicopathological characteristics of gastric cancer for different SIS scores were reported by a limited number of studies. Our meta-analysis of 2–4 studies showed that high SIS scores was associated with older age (≥70 years) (OR: 2.32 95% CI: 1.93, 2.79, I² = 0%), male gender (OR: 1.49 95% CI: 1.09, 2.02, I² = 46%), and tumor size ≥5 cm (OR: 2.86 95% CI: 2.34, 3.50, I² = 0%); while low SIS was associated with poorly differentiated gastric cancer (OR: 0.76 95% CI: 0.65, 0.90 I² = 0%) (Figure 2). SIS did not correlate with lower third tumor location (OR: 1.25 95% CI: 0.89, 1.77, I² = 55%), lymph node metastasis (OR: 1.33 95% CI: 0.61, 2.91, I² = 84%), or tumor stage III (OR: 1.46 95% CI: 0.85, 2.51, I² = 83%).

OS

Four studies compared the prognostic ability of SIS scores 1 and 2 vs. 0 for OS. On meta-analysis, we noted that SIS scores of 1 (HR: 1.25 95% CI: 1.05, 1.49, I² = 11%) and 2 (HR: 1.43 95% CI: 1.04, 1.98, I² = 54%) were associated with statistically significant poor OS as compared to those with SIS score of 0 (Figure 3). Hara et al. (19) comparing SIS scores of 1/2 vs. 0 noted a significant association between higher scores and poor OS (HR: 2.14 95% CI: 1.13, 4.08). Combining all the above data we noted that higher SIS scores (1 or 2) were significant predictors of poor OS in gastric cancer patients (HR: 1.25 95% CI: 1.05, 1.49, I² = 11%) (Figure 3). On sensitivity analysis for the entire data, we noted that the final result was still statistically significant on the exclusion of any of the included data. Two studies compared the SIS score of 2 vs. 0/1. The meta-analysis demonstrated that an SIS score of 2 was associated with poor OS as compared to scores of 0/1 (HR: 2.53 95% CI: 1.30, 4.89, I² = 45%) (Figure 4).

DFS

Data on DFS was reported by a limited number of studies with varying comparisons which precluded a meta-analysis. Hara et al. (19) noted that the SIS score of 1/2 vs. 0 was not predictive of DFS (HR: 1.814 95% CI: 0.993–3.315) in gastric cancer patients. Sato et al. (16) also have shown that the SIS score of 2 vs. 0/1 was not associated with poor DFS (HR: 1.58 95% CI: 0.78–3.07). However, Ma et al. (17) noted that an SIS score of 2 was significantly associated with poor DFS as compared to those with scores of 0/1.

Discussion

Most clinicians classify gastric cancer based on the pathological TNM staging system to determine patient prognosis and the need for additional therapies (23). Nevertheless, it is not uncommon to find varying OS and DFS in gastric cancer patients with the same tumor stage (24). This is somewhat attributable to the limitation of TNM staging which is based on the biological characteristics of the malignancy and does not incorporate the host and tumor inflammatory response (7). Indeed, the interaction between cancer and inflammation is quite complex. Systemic
inflammatory changes can either herald the development of cancer or the malignancy itself can lead to a tumor-promoting inflammatory environment. Cancer cells produce pro-mediators like interleukins, transforming growth factor-β, macrophage migratory inhibitory factors, proteases, and eicosanoids which creates a pro-inflammatory environment that aids in the multiplication and survival of cancer cells, promotes angiogenesis and metastasis, attenuates adaptive immunity, and also changes the tumor response to hormones and chemotherapy (25). One way of estimating the inflammatory status of an individual is by measuring the cellular along with non-cellular elements of blood which are reflective of the immune and inflammatory status of the body. Kim et al. (8) in a meta-analysis have shown that NLR, CRP,
### TABLE 1 Details of included studies.

| Study | Location | Study population | Tumor stage | SIS definition | Timing of SIS | Sample size | Age (years) | Male gender (%) | Adeno-carcinoma (%) | Poorly differentiated (%) | Location U/M/L/Mix | Total gastrectomy (%) | AC (%) | Median follow-up (months) | NOS score |
|-------|----------|------------------|-------------|----------------|--------------|-------------|-------------|-------------------|-----------------------|------------------------|-----------------------|----------------------|---------|---------------------------|-----------|
| He 2022 | China | Early stage gastric cancer | I–II | 0: AL ≥ 40 g/dl & LMR ≥ 4.44 1: either AL ≥ 40 g/dl or LMR ≥ 4.44 2: AL < 40 g/dl & LMR < 4.44 | Pre-surgery | 358 | 61 | 79.3 | 74 | 70.7 | 17/04/144/0 | NR | 4.4 | 101 | 8 |
| Lin 2021 | China | Primary gastric adenocarcinoma | I–III | 0: AL ≥ 40 g/dl & LMR ≥ 4.44 1: either AL ≥ 40 g/dl or LMR ≥ 4.44 2: AL < 40 g/dl & LMR < 4.44 | Pre-surgery | 2180 | NR | 74.8 | 100 | 22.2 | 50/46/1593/281 | 51.1 | 53.4 | 54 | 8 |
| Inagaki 2021 | Japan | Gastric adenocarcinoma | I–III | 0: AL ≥ 40 g/dl & LMR ≥ 3.4 1: either AL ≥ 40 g/dl or LMR ≥ 3.4 2: AL < 40 g/dl & LMR < 3.4 | Pre-surgery | 1764 | 67.3 | 70.3 | 100 | 48.8 | NR/NR/622/NR | 27.2 | 27.5 | 62.9 | 8 |
| Hara 2020 | Japan | Advanced gastric cancer | II–III | 0: AL ≥ 40 g/dl & LMR ≥ 4.44 1: either AL ≥ 40 g/dl or LMR ≥ 4.44 2: AL < 40 g/dl & LMR < 4.44 | 1 month post-surgery | 160 | 67 | 63.7 | 100 | 61.9 | NR | 47.5 | 77.5 | NR | 7 |
| Chen 2020 | China | Gastric adenocarcinoma | I–IV | 0: AL ≥ 40 g/dl & LMR ≥ 4.44 1: either AL ≥ 40 g/dl or LMR ≥ 4.44 2: AL < 40 g/dl & LMR < 4.44 | Pre-surgery | 358 | 59 | 62.3 | 100 | 63.1 | 60/34/159/99 | 45 | 24 | 35 | 7 |

(continued)
| Study Location Study population Tumor stage | SIS definition | Timing of SIS | Sample size | Age (years) | Male gender (%) | Adenocarcinoma (%) | Poorly differentiated (%) | Location U/M/L/Mix | Total gastrectomy (%) | AC (%) | Median follow-up (months) | NOS score |
|--------------------------------------------|----------------|---------------|-------------|-------------|----------------|-------------------|------------------------|---------------------|----------------------|---------|---------------------------|-----------|
| Ma 2019 China Gastric adenocarcinoma I-III | 0: Al ≥ 40 g/dl & LMR ≥ 4.44 1: either Al ≥ 40 g/dl or LMR ≥ 4.44 2: Al < 40 g/dl & LMR < 4.44 | Pre-surgery | 331 | 55.3 | 68.9 | 100 | 48.3 | 52/279 | NR | NR | 61.2 | 8 |
| Sato 2018 Japan pT2-4 gastric cancer I-III | 0: Al ≥ 40 g/dl & LMR ≥ 4.44 1: either Al ≥ 40 g/dl or LMR ≥ 4.44 2: Al < 40 g/dl & LMR < 4.44 | Pre-surgery | 187 | 69 | 78.1 | NR | 62 | 60/83/81/3 | 37 | 47 | 45.2 | 8 |

AC, adjuvant chemotherapy; Al, albumin; LMR, lymphocyte-monocyte ratio; SIS, systemic inflammation score; NOS, Newcastle Ottawa scale; U, upper; M, middle; L, lower; NR, not reported.
FIGURE 2

Meta-analysis assessing the relationship between high SIS and clinicopathological features of gastric cancer namely, age (≥70 years vs. <70 years), gender (male vs. female), tumor size (≥5 cm vs. <5 cm), location (lower third vs. other sites), differentiation (poorly differentiated vs. well differentiated), lymph node metastasis (present vs. absent), and tumor stage (stage III vs. stage I–II). Blue boxes indicate the point estimates of individual studies and horizontal lines denote the confidence intervals. Black diamond indicates the total effect size.

| Study or Subgroup | High SIS | Low SIS | Odds Ratio | Year |
|-------------------|----------|---------|------------|------|
|                    | Events   | Total   | Weight IV  | Random, 95% CI |
| 1.3.1 Age ≥70     | 64       | 109     | 25         | 78    | 9.0% | 3.02 [1.64, 5.55] | 2018 |
| Sato 2018         | 456      | 809     | 347        | 955   | 91.0%| 2.26 [1.87, 2.74] | 2021 |
| Inagaki 2021      | 918      | 1033    | 100.0%     |       |     | 2.32 [1.93, 2.79] |     |
| Total events      | 520      | 372     |            |       |     |                |     |
| Heterogeneity: Tau² = 0.00; Chi² = 0.77, df = 1 (P = 0.38); I² = 0% |
| Test for overall effect: Z = 9.04 (P < 0.00001) |
| 1.3.2 Male gender | 90       | 109     | 56         | 78    | 14.4%| 1.86 [0.93, 3.74] | 2018 |
| Sato 2018         | 158      | 233     | 65         | 125   | 25.6%| 1.94 [1.25, 3.04] | 2020 |
| Chen 2020         | 57       | 93      | 45         | 67    | 15.6%| 0.77 [0.40, 1.50] | 2020 |
| Hara 2020         | 605      | 809     | 635        | 955   | 44.4%| 1.49 [1.21, 1.84] | 2021 |
| Inagaki 2021      | 1244     | 1225    | 100.0%     |       |     | 1.49 [1.09, 2.02] |     |
| Total events      | 910      | 801     |            |       |     |                |     |
| Heterogeneity: Tau² = 0.04; Chi² = 5.54, df = 3 (P = 0.14); I² = 46% |
| Test for overall effect: Z = 2.54 (P = 0.01) |
| 1.3.3 Tumor size ≥5cm | 56      | 109     | 17         | 78    | 9.4% | 3.79 [1.97, 7.30] | 2018 |
| Sato 2018         | 333      | 809     | 192        | 955   | 90.6%| 2.78 [2.25, 3.43] | 2021 |
| Inagaki 2021      | 918      | 1033    | 100.0%     |       |     | 2.86 [2.34, 3.50] |     |
| Total events      | 389      | 209     |            |       |     |                |     |
| Heterogeneity: Tau² = 0.00; Chi² = 0.78, df = 1 (P = 0.38); I² = 0% |
| Test for overall effect: Z = 10.25 (P < 0.00001) |
| 1.3.4 Lower third location | 43      | 109     | 18         | 78    | 19.0%| 2.17 [1.13, 4.17] | 2018 |
| Sato 2018         | 106      | 233     | 59         | 125   | 30.6%| 0.93 [0.60, 1.44] | 2020 |
| Chen 2020         | 305      | 809     | 317        | 955   | 50.4%| 1.22 [1.00, 1.48] | 2021 |
| Inagaki 2021      | 1151     | 1158    | 100.0%     |       |     | 1.25 [0.89, 1.77] |     |
| Total events      | 454      | 394     |            |       |     |                |     |
| Heterogeneity: Tau² = 0.05; Chi² = 4.45, df = 2 (P = 0.11); I² = 55% |
| Test for overall effect: Z = 1.29 (P = 0.20) |
| 1.3.5 Poorly differentiated | 62      | 109     | 54         | 78    | 7.0% | 0.59 [0.32, 1.08] | 2018 |
| Sato 2018         | 139      | 233     | 87         | 125   | 12.3%| 0.65 [0.41, 1.03] | 2020 |
| Chen 2020         | 54       | 93      | 45         | 67    | 6.1% | 0.68 [0.35, 1.30] | 2020 |
| Hara 2020         | 372      | 809     | 489        | 955   | 74.6%| 0.81 [0.67, 0.98] | 2021 |
| Inagaki 2021      | 1244     | 1225    | 100.0%     |       |     | 0.76 [0.65, 0.90] |     |
| Total events      | 627      | 675     |            |       |     |                |     |
| Heterogeneity: Tau² = 0.00; Chi² = 1.75, df = 3 (P = 0.63); I² = 0% |
| Test for overall effect: Z = 3.28 (P = 0.001) |
| 1.3.6 Lymph node metastasis | 67      | 109     | 51         | 78    | 43.4%| 0.84 [0.46, 1.55] | 2018 |
| Sato 2018         | 378      | 809     | 303        | 955   | 56.6%| 1.89 [1.55, 2.29] | 2021 |
| Inagaki 2021      | 918      | 1033    | 100.0%     |       |     | 1.33 [0.61, 2.91] |     |
| Total events      | 445      | 354     |            |       |     |                |     |
| Heterogeneity: Tau² = 0.27; Chi² = 6.15, df = 1 (P = 0.01); I² = 84% |
| Test for overall effect: Z = 0.72 (P = 0.47) |
| 1.3.7 Stage III tumor | 50      | 109     | 34         | 78    | 22.9%| 1.10 [0.61, 1.97] | 2018 |
| Sato 2018         | 94       | 233     | 49         | 125   | 25.7%| 1.05 [0.67, 1.64] | 2020 |
| Chen 2020         | 54       | 93      | 34         | 67    | 21.9%| 1.34 [0.71, 2.53] | 2020 |
| Hara 2020         | 263      | 809     | 151        | 955   | 29.5%| 2.56 [2.04, 3.22] | 2021 |
| Inagaki 2021      | 1244     | 1225    | 100.0%     |       |     | 1.46 [0.85, 2.51] |     |
| Total events      | 461      | 268     |            |       |     |                |     |
| Heterogeneity: Tau² = 0.25; Chi² = 18.07, df = 3 (P = 0.0004); I² = 83% |
| Test for overall effect: Z = 1.36 (P = 0.17) |

0.01 0.1 1 10 100
Favours [Low SIS]  Favours [High SIS]
and Glasgow prognostic scores correlate with poor OS in gastric cancer patients. Qiu et al. (26) have demonstrated that the systemic-immune inflammation index is a significant predictor of poor OS but not DFS in gastric cancer. Cao et al. (27) have shown that PLR is also an independent predictor of poor OS in gastric cancer patients.

Another novel marker that has been used in recent years is the SIS. The SIS combines albumin and LMR values and has been noted to be superior to other blood-borne markers like the NLR, modified Glasgow Prognostic Score, and lymphocyte C-reactive protein score for patients with cancer (18, 28). Its prognostic ability has also been validated in several cancer subtypes. Xiong et al. (29) have shown that the SIS can be a simple and useful scoring system to predict OS and DFS in patients with adenocarcinoma of the esophagogastric junction. Feng et al. (12) found the SIS to be an independent predictor of survival and adverse events in patients with rectal cancer. Li et al. (13) have shown that a step-wise increase in SIS significantly shortened OS and DFS in lung-cancer patients undergoing surgical intervention. Similar results have been noted for patients with pancreatic and hepatic cancer as well (30, 31).

Our review, which is the first one to combine data on the prognostic ability of SIS for gastric cancer, concurs with the above-mentioned studies. We noted that SIS was a significant predictor of OS in gastric cancer patients undergoing surgery.
Despite including seven studies, we could not combine data in a single meta-analysis due to differences in the reference groups. Our analysis indicated that SIS scores of either 1 or 2 predicted poor OS but the difference in overall HR was not much. The score of 1 vs. 0 had an HR of 1.25 while 2 vs. 0 had an HR of 1.43. Overall a patient with a high SIS score (1 or 2) had a 36% increased risk of mortality. We also noted that patients with a score of 2 as compared to 0/1 had a higher risk of mortality (HR: 2.53) but data was quite limited. Overall, the study population in the included studies was more or less homogenous in terms of study location, tumor stage, the timing of SIS, and histopathological subtype. All studies were on Asian populations and commonly included stage I–III patients. Most patients had adenocarcinoma and all underwent surgical intervention. Except for one study (19), SIS was measured before surgery in all studies. Also, only one study used the modified version of the SIS. The effects of these singular studies were analyzed using the sensitivity analysis which failed to demonstrate any change in the results. Furthermore, due to a homogenous study population and a limited number of studies in the meta-analysis, we were unable to conduct a subgroup analysis to further decipher the results. Secondly, data on DFS was scarcely reported in the literature with two of three studies noting no association between SIS and DFS. Owing to limited data, strong conclusions cannot be drawn till further studies are published.

Poor prognosis of gastric cancer with high SIS scores could be due to poor patient characteristics and advanced disease stage in such patients. To explore this, we compared the clinicopathological features between high and low SIS scores. Importantly, data was very scarce and the meta-analysis could include just 2–4 studies for each variable. On one hand we noted that larger tumor size correlated with high SIS scores but higher incidence of poorly differentiated tumor was seen in patients with low SIS scores. Also, higher tumor stage did not correlate with SIS scores. Such variability in the results could be primarily due to the scarce data available. Additional data is needed to explore the relationship between gastric cancer features and SIS scores.

The prognostic ability of SIS lies in its combined use of albumin and LMR values. Research indicates SIS is better than individual components for predicting the prognosis (29). The albumin component in SIS indicates the inflammatory as well as the nutritional state of the patient. Hypoalbuminemia is reflective of the presence of malnutrition and cachexia in a cancer patient and is known to be associated with survival outcomes in gastric cancer (32). LMR has two components: lymphocyte and monocyte count. The basic structure of innate and adaptive immunity in an individual is based on lymphocytes which have roles in immune surveillance and immune editing. Lymphocytes have anti-oncogenic potential wherein they limit the growth, invasion, and metastasis of cancer cells (33). The presence of tumor-infiltrating lymphocytes is known to improve the prognosis of cancer patients (34). In contrast to lymphocytes, the presence of monocytes accelerates the growth of tumors by reducing immune surveillance. By means of tumor-monocyte-endothelial interaction, high monocyte counts can increase the risk of metastasis (35, 36). Owing to these postulations, low LMR which is because of low lymphocyte and high monocyte count may lead to poor prognosis in cancer patients.

The primary strength of our review is that it is the first study to pool evidence on the role of SIS in predicting the prognosis of cancer patients. A detailed literature search was undertaken to include maximum studies and a separate analysis of only adjusted outcomes based on reference groups was conducted, thereby presenting high-quality evidence to clinicians. However, there are limitations as well. Our review could include only seven studies all of them retrospective in nature. Retrospective study designs have an inherent bias that cannot be nullified. Study origins only from two countries restrict the generalizability of the results. Also, our inability to perform subgroup analyses due to limited data is another drawback. Lastly, a meta-analysis for DFS could not be conducted, again due to the unavailability of data.

Conclusions

The SIS score can be a simple and useful tool to predict OS in gastric cancer patients undergoing surgery. Data on DFS is scarce and conflicting. Future studies should report using standard reference groups and provide data on DFS to enhance current evidence.

Author contributions

SL and LJ conceived and designed the study. SL, XY, FY and LJ collected the data and performed the analysis. LJ was involved in the writing of the manuscript and is responsible for the integrity of the study. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their
affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Petryszyn P, Chapelle N, Matsyiak-Budnik T. Gastric cancer: where are we heading? Dig Dis. (2020) 38:280–5. doi: 10.1159/000506509
2. Lin Y, Zheng Y, Liang WH, Wu J. Global patterns and trends in gastric cancer incidence rates (1988–2012) and predictions to 2030. Gastroenterology. (2021) 161:116–27.e8. doi: 10.1053/J.GASTRO.2021.03.023
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. (2016) 66:115–32. doi: 10.3322/CAAC.21338
4. Mullaney PJ, Wadley MS, Hyde C, Wyatt J, Lawrence G, Hallissey MT, et al. Appraisal of compliance with the UKCC/AACC staging system in the staging of gastric cancer. Union internacional contra la cancerim/American joint committee on cancer. Br J Surg. (2002) 89:1405–23. doi: 10.1046/J.1365-2168.2002.02262.X
5. Hernández M, Martín R, García-Cubillas MD, Maeso-Hernández P, Nieto ML. Secreted PLA2 induces proliferation in astrocytoma through the EGFP receptor; another inflammation-cancer link. Neuro Oncol. (2010) 12:1014–23. doi: 10.1093/NEURO Onc/NOQ078
6. Liu S, Li C, Zhang P. Enhanced recovery after surgery for hip fractures: a systematic review and meta-analysis. Perioper Med. (2021) 10.3186/513741-021-00216-8
7. McMillan DC. Cancer and systemic inflammation: stage the tumour and stage the host. Br J Cancer. (2013) 109:529. doi: 10.1038/bjc.2013.418
8. Kim MR, Kim AS, Choi HI, Jung JH, Park JY, Ko HJ. Inflammation-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis. PLoS One. (2020) 15:e0236445. doi: 10.1371/JOURNAL.PONE.0236445
9. Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and predicts overall survival in patients with advanced gastric cancer. BMC Cancer. (2019) 19:672. doi: 10.1186/s12888-019-5903-Y
10. Jiang Y, Xu D, Song H, Qiu B, Tian D, Li Z, et al. Inflammation and nutrition-based biomarkers in the prognosis of esophageal cancer: a systematic review and meta-analysis. BJU Int. (2021) 11:e048324. doi: 10.1111/BMJOPEN.2020-048324
11. Nomoto D, Baba Y, Akiyama T, Okado K, Iwasuki M, Iwagami S, et al. Adapted systemic inflammation score as a novel prognostic marker for esophageal squamous cell carcinoma patients. Ann Gastroenterol Surg. (2021) 5:669–76. doi: 10.1002/AGS.12464
12. Feng Y, Liu L, Zha Y. Systemic inflammation score in locally advanced rectal cancer patients following total mesorectal excision. Onco Targets Ther. (2019) 12:6617–22. doi: 10.2147/OTT.S213720
13. Li S, Zhang W, Yang Z, Li Y, Du H, Che G. Systemic inflammation score as a novel prognostic indicator for patients undergoing video-assisted thoracoscopic surgery lobectomy for non-small-cell lung cancer. J Invest Surg. (2021) 34:248–40. doi: 10.1080/0899329X.2019.1641169
14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. (2021) 88:105906. doi: 10.1016/j.ijsu.2021.105906
15. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. (Accessed October 30, 2020).
16. Sato B, Kanda M, Tanaka C, Kobayashi D, Iwata N, Hattori N, et al. Significance of preoperative systemic inflammation score in short-term and long-term outcomes of patients with pathological T2-4 gastric cancer after radical gastrectomy. World J Surg. (2018) 42:5277–85. doi: 10.1007/S00268-018:4597-7
17. Ma M, Weng M, Chen F, Hu Y, Lai J, Wang Y, et al. Systemic inflammation score is a prognostic marker after curative resection in gastric cancer. ANZ J Surg. (2019) 89:377–82. doi: 10.1111/ANS.15103
18. Chen YR, Chen YL, Ouyang SS, Xu HW, Li P, He LJ, et al. Prognostic efficacy of preoperative nGPS, SIS and LCS in patients with gastric cancer. Chin Chir Acta. (2020) 51:81–9. doi: 10.1016/J.CCCA.2020.09.027
19. Hara K, Arayama T, Yamada T, Nakazono M, Nagasawa S, Shimoda Y, et al. The prognostic value of the perioperative systemic inflammation score for patients with advanced gastric cancer. Anticancer Res. (2020) 40:1503–12. doi: 10.21873/ANTICANRES.14095
20. Inagaki K, Kanda M, Nakashima K, Ito S, Mochizuki Y, Teramoto H, et al. Accurate prediction of prognosis after radical resection of gastric cancer by the modified systemic inflammation score; a multicenter dataset analysis. World J Surg. (2021) 45:2513–20. doi: 10.1007/S00268-021-06138-9
21. Lin JX, Huang YQ, Wang ZK, Xie W, Bin WJ, Lu J, et al. Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer. J Surg Oncol. (2021) 124:282–92. doi: 10.1002/JSU2.26498
22. He K, Li L, Pan X, Sun L, Wang Y, Lu J, et al. Preoperative systemic immune-inflammation index (SII) as a superior predictor of long-term survival outcome in patients with stage I-II gastric cancer after radical surgery. Front Oncol. (2022) 12:829689. doi: 10.3389/FONC.2022.829689
23. Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. (2017). 39:1010428317714626
27. Cao W, Yao X, Cen D, Zhi Y, Zhu N, Xu L. The prognostic role of platelet-to-lymphocyte ratio on overall survival in gastric cancer: a systematic review and meta-analysis. BMC Gastroenterol. (2020) 20:16. doi: 10.1186/S12876-020-1167-X
28. Fu X, Li T, Dai Y, Li J. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma. BMC Cancer. (2019) 19:721. doi: 10.1186/S12885-019-5940-6
29. Xiong J, Kang W, Ma F, Liu H, Ma S, Li Y, et al. Modified systemic inflammation score is an independent predictor of long-term outcome in patients undergoing surgery for adenocarcinoma of the esophageogastic junction. Front Surg. (2021) 8:622821. doi: 10.3389/FPSURG.2021.622821
30. Markus M, Abendroth A, Noureddine R, Paul A, Breitenbuecher S, Vuschow J, et al. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy. J Cancer Res Clin Oncol. (2021) 147:579–91. doi: 10.1007/S00034-020-03361-0
31. Zhang Y, Shi SM, Yang H, Yang L, Wang Z, Li XD, et al. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection. J Cancer. (2019) 10:494–503. doi: 10.7150/JCA.26890
32. Liu C, Li X. Stage-dependent changes in albumin, NLR, PLR, and AFR are correlated with shorter survival in patients with gastric cancer. Chin Lab. (2019) 65:1623–33. doi: 10.7754/CLIN.LAB.2019.190132

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.971326/full#supplementary-material.
33. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity*. (2004) 21:137–48. doi: 10.1016/J.IMMUNI.2004.07.017

34. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. *J Clin Oncol*. (2012) 30:2678–83. doi: 10.1200/JCO.2011.37.8539

35. Evani SJ, Prabhuj RG, Gnanaruban V, Finol EA, Ramasubramanian AK. Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. *FASEB J*. (2013) 27:3017–29. doi: 10.1096/FJ.12-224824

36. Augier S, Ciucci T, Luci C, Carle GF, Blin-Wakkach C, Wakkach A. Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. *J Immunol*. (2010) 185:7165–73. doi: 10.4049/JIMMUNOL.0902583